University of Adelaide researchers have designed a new molecule which targets a protein essential to the growth of most cancers. The protein target is called proliferating cell nuclear antigen (PCNA), also known as the human sliding clamp.
ElectroCore, famous for bioelectronic medicines, is associating with UpScriptHealth to deliver its gammaCore treatment via direct-to-patient telemedicine program. This non-invasive stimulation therapy of vagus nerve is used to treat migraines and episodic cluster headaches among the adults.
In the United States alone, there are an estimated 20,000 people living with amyotrophic lateral sclerosis (ALS), also called as Lou Gehrig's disease. The fatal disease destroys the nerve cells which control breathing, walking, and eating. Very few people survive more than three years after being diagnosed.
Johnson & Johnson is moving out from the diabetes business and sold its Calibra product (marketed as OneTouch Via, but never launched) to a 10-year-old company named CeQur, which was already working on a similar insulin-delivery wearable. The terms and conditions of this deal have not yet been yet disclosed, but CeQur has attained an exclusive worldwide license for this technology.
HCC or hepatocellular carcinoma can result in patients getting liver diseases such as viral hepatitis and non-alcoholic fatty liver disease with cirrhosis due to disease progression. New data from recent researches shows factors that improve early detection and diagnosis, and risks prior to HCC and during treatment.
Spero Therapeutics granted $15.7 million for research on SPR994, its oral carbapenem-class candidate, to study the drug’s efficacy against biological threats like anthrax, plague and melioidosis as a part of an interagency collaboration.
If a drop of blood is seen in stool, people tend to panic. The causative factors could include digestive, respiratory, circulatory, hematological or even neuropsychological diseases.
San Francisco based Verge Genomics, the Neuroscience based drug discovery company launched in 2015, has raised $32 million in early venture capital financing to bring its AI-generated compounds against Parkinson’s disease and amyotrophic lateral sclerosis (ALS) to clinics within the next three years.
A digital era in the medical field has arisen where one could find the increased utilization of health apps. But a recent analysis by a research team from the University of Sydney in Australia claims that these apps might lead to insignificant diagnosis and wrong information about the illness.
Viral hepatitis is a major global health issue since it is the seventh leading cause of death worldwide. Around half of hepatitis-related deaths reported are due to the hepatitis B virus infection, which is transmitted through blood and body fluids.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.